Skip to main content
Caplight Logo









Innolake Biopharm

Innolake Biopharm

Private
HangzhouHealthcare & Life Scienceshttps://www.innolakebio.com/

Last Round

Series A

Extension

Jun 5, 2023

Total Funding Raised

$53.99M

Company Overview

Innolake Biopharm is a clinical-stage biotechnology company that develops therapeutic drugs for cancer and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antibody-drug conjugateADConcology drug developmentbiotech licensingmonoclonal antibodiessmall molecule discoveryclinical-stage biotechautoimmune disease therapeuticsdrug discovery platformfirst-in-class drugsbiopharma partneringout-licensingsolid tumor treatmentB7H3 inhibitorA2aR antagonist

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Innolake Biopharm Comparables

Compare Innolake Biopharm with similar companies based on industry and business-model similarity.

Innolake Biopharm comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
MediLink Therapeutics
88%
Minghui Pharmaceutical
86%
Duality Biotherapeutics Inc
85%

Innolake Biopharm Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionJun 5, 2023
Early FundingApr 6, 2021

Key People

Founding team and executive leadership

Mingde Xia

Founder, Chairman And CEO

Founding Team

Innolake Biopharm Investors

Notable investors and investment history

Innolake Biopharm investors
InvestorRounds
Zhongbo JuliSeries A Extension
Hangzhou Heda Industry FundSeries A Extension
Huagai CapitalEarly Funding
CDH InvestmentsEarly Funding
Zhongbo Venture CapitalSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 5, 2023

    $14M round led by Zhongbo Juli and Hangzhou Heda Industry Fund.

  • Apr 6, 2021

    $40M raised with participation from CDH Investments and Huagai Capital.

Innolake Biopharm Filings

Explore SEC and related filing metadata, where available.

Innolake Biopharm filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Innolake Biopharm's valuation, stock price, and market status.

Is Innolake Biopharm a public or private company?

Innolake Biopharm is a private company.

What is the current stock price of Innolake Biopharm?

Innolake Biopharm is a private company with no public stock price. No recent secondary market data is available.

How much is Innolake Biopharm worth (valuation)?

Valuation information for Innolake Biopharm is not publicly available.

Can I buy Innolake Biopharm stock?

Innolake Biopharm shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Innolake Biopharm's last funding round?

Innolake Biopharm's most recent funding round was Series A Extension on June 5, 2023.

Who are the main investors in Innolake Biopharm?

Key investors in Innolake Biopharm include Hangzhou Heda Industry Fund, Zhongbo Venture Capital.

Will Innolake Biopharm IPO soon?

No public IPO plans have been announced for Innolake Biopharm.

How can I track Innolake Biopharm secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Innolake Biopharm's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHangzhou
Employee Range4
Year Founded2020
Last FundingJun 5, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?